U.S. SEC Commissioner Hester Peirce: Worked with Acting Chairman Paul Atkins for four years, hoping to continue promoting "Safe Harbor" to encourage crypto innovation
According to Coindesk, Hester Peirce, a commissioner of the U.S. Securities and Exchange Commission (SEC), said in an interview at the end of February that she still believes a "safe harbor" should be established to promote cryptocurrency innovation, but is not fixated on this idea. If people have better ideas they can propose them; the SEC's goal is for people to genuinely want to disclose information without worrying about becoming targets of SEC enforcement actions if they do.
In addition, Hester Peirce revealed that she had worked for four years for current acting SEC Chairman Paul Atkins, describing him as someone who likes clear laws and then enforces them.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
